Tinavi Medical Technologies Co., Ltd. (688277.SH) Latest Company News

Oct 28, 2026, 09:47 UTC
Tianzhihang reported that its Tianji orthopedic surgical robot was used in more than 17,000 surgeries in the third quarter of 2026, bringing cumulative procedures to nearly 200,000 by the reporting-period end.
Source:
- finance.sina.cn
Oct 28, 2026, 09:47 UTC
Tianzhihang reported first-nine-month 2026 research and development spending of RMB 104 million, up 19.17% year over year and equal to 58.75% of revenue.
Source:
- finance.sina.cn
Oct 28, 2026, 09:47 UTC
Tianzhihang reported third-quarter and first-nine-month 2026 results, including revenue of RMB 71.2658 million and RMB 177 million, respectively, and net losses of RMB 25.4196 million and RMB 95.5255 million.
Source:
- finance.sina.cn
Sep 27, 2026, 07:38 UTC
Tianzhihang plans to acquire a 62% stake in Shanghai MicroPort Orthopedics Medical Technology through a share issuance and raise matching funds, with the deal expected to constitute a major asset restructuring and related-party transaction.
Source:
- finance.sina.cn
Sep 7, 2026, 10:42 UTC
Tianzhihang announced a change of its legal representative to general manager Xu Jin, effective after the amendment of the company's articles of association.
Source:
- finance.sina.cn
Aug 25, 2026, 10:27 UTC
Tianzhihang reported a net loss of 70.1059 million yuan for the first half of 2026, compared with a loss of 57.5482 million yuan in the same period of 2025.
Source:
- finance.sina.cn
- wap.eastmoney.com
Aug 6, 2026, 08:53 UTC
Tianzhihang received a medical device registration certificate from China's National Medical Products Administration for its orthopedic surgery planning software, valid until August 3, 2031.
Source:
- finance.sina.cn
Jul 16, 2026, 02:09 UTC
MicroPort Scientific announced that its subsidiary Suzhou MicroPort and TINAVI Medical Technologies have signed a letter of intent for TINAVI's potential acquisition of equity in Shanghai MicroPort Orthopedic Medical Technology, with consideration to be paid in new TINAVI shares.
Source:

688277.SH

Tianzhihang reported that its Tianji orthopedic surgical robot was used in more than 17,000 surgeries in the third quarter of 2026, bringing cumulative procedures to nearly 200,000 by the reporting-period end.

Tianzhihang reported first-nine-month 2026 research and development spending of RMB 104 million, up 19.17% year over year and equal to 58.75% of revenue.

Tianzhihang reported third-quarter and first-nine-month 2026 results, including revenue of RMB 71.2658 million and RMB 177 million, respectively, and net losses of RMB 25.4196 million and RMB 95.5255 million.

Tianzhihang plans to acquire a 62% stake in Shanghai MicroPort Orthopedics Medical Technology through a share issuance and raise matching funds, with the deal expected to constitute a major asset restructuring and related-party transaction.

Tianzhihang announced a change of its legal representative to general manager Xu Jin, effective after the amendment of the company's articles of association.

Tianzhihang reported a net loss of 70.1059 million yuan for the first half of 2026, compared with a loss of 57.5482 million yuan in the same period of 2025.

Tianzhihang received a medical device registration certificate from China's National Medical Products Administration for its orthopedic surgery planning software, valid until August 3, 2031.

MicroPort Scientific announced that its subsidiary Suzhou MicroPort and TINAVI Medical Technologies have signed a letter of intent for TINAVI's potential acquisition of equity in Shanghai MicroPort Orthopedic Medical Technology, with consideration to be paid in new TINAVI shares.